Article
Biophysics
Jeremy L. Ramdial, Rohtesh S. Mehta, Rima M. Saliba, Amin M. Alousi, Qaiser Bashir, Chitra Hosing, Partow Kebriaei, Amanda L. Olson, Betul Oran, Muzaffar H. Qazilbash, Samer A. Srour, Borje S. Andersson, Richard E. Champlin, Uday Popat
Summary: The study identified that the majority of patients experiencing NRM between days 101 and 365 post-HCT had a history of grade II-IV acute GVHD, which was the leading cause of death. Acute GVHD was found to be the only significant predictor of NRM between days 101 and 365 in multivariate analysis. Measures to reduce the risk of acute GVHD could help lower the risk of NRM at 1 year and improve overall survival.
BONE MARROW TRANSPLANTATION
(2021)
Article
Immunology
Yu Akahoshi, Shun-Ichi Kimura, Yoshihiro Inamoto, Sachiko Seo, Hiroyuki Muranushi, Hiroaki Shimizu, Yukiyasu Ozawa, Masatsugu Tanaka, Naoyuki Uchida, Yoshinobu Kanda, Yuta Katayama, Souichi Shiratori, Shuichi Ota, Ken-ichi Matsuoka, Makoto Onizuka, Takahiro Fukuda, Yoshiko Atsuta, Makoto Murata, Seitaro Terakura, Hideki Nakasone
Summary: The study highlights the close relationship between acute GVHD and CMVR, providing important implications for post-transplant treatment strategies.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Oncology
Bo Peng, Liping Dou, Jingjing Yang, Lili Wang, Fei Li, Xiaoning Gao, Shuhong Wang, Xiangshu Jin, Lu Wang, Mingyu Jia, Shenyu Wang, Yan Li, Daihong Liu
Summary: This study aimed to identify the incidence, risk factors, and impacts of recurrence of acute graft-versus-host disease (RaGVHD) after haploidentical hematopoietic cell transplantation (haplo-HCT). The study found that RaGVHD was common and associated with higher grades of aGVHD and an increased risk of GVHD-related deaths.
HEMATOLOGICAL ONCOLOGY
(2022)
Review
Immunology
Allen Cheng-Wei Li, Chen Dong, Soon-Tzeh Tay, Ashwin Ananthakrishnan, Kevin Sheng-Kai Ma
Summary: This study aimed to evaluate the safety and efficacy of vedolizumab for GI-aGVHD. The results showed that vedolizumab treatment significantly improved the overall response rate, complete response rate, and survival rate of patients with GI-aGVHD. Prophylactic use of vedolizumab did not have specific adverse events, but patients with GI-aGVHD on vedolizumab had an increased risk of infections and impaired metabolism or nutritional complications during treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Aditya Rayasam, William R. Drobyski
Summary: GVHD, driven by alloreactive donor T cells, results in inflammatory damage to the skin, GI tract, lung, and liver, with the GI tract as a primary target organ. Prevention strategies focusing on the GI tract have become crucial in mitigating the morbidity and mortality associated with GVHD.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Francesca Maccioni, Ursula La Rocca, Alberto Milanese, Ludovica Busato, Arianna Cleri, Mariangela Lopez, Lucia Manganaro, Carlo De Felice, Cira Di Gioia, Anna Rita Vestri, Carlo Catalano, Anna Paola Iori
Summary: This study evaluated the value of magnetic resonance imaging (MRI) in the diagnosis, staging, and prediction of acute gastrointestinal graft-versus-host disease (GI-aGVHD). The results showed that MRI has high sensitivity and specificity in diagnosing GI-aGVHD and assessing disease severity.
EUROPEAN RADIOLOGY
(2023)
Article
Multidisciplinary Sciences
Andreas Kreft, Katrin Hippe, Eva Maria Wagner-Drouet, Isabelle Ries, Arne Kandulski, Maike Buettner-Herold, Helmut Neumann, Daniela Weber, Ernst Holler, Mario Schindeldecker
Summary: Multiple simultaneous colon biopsies improve diagnostic sensitivity in patients with acute graft versus host disease (aGvHD). Higher histological grades are associated with steroid therapy initiation and refractoriness, particularly when advanced damage is present in all samples. The Lerner system is generally superior to other grading methods for predicting treatment response and outcome.
Article
Pharmacology & Pharmacy
Rongrong Wang, Depei Wu, Jianfeng Dai, Jiaqi Shen, Jianjie Rong, Zixing Chen, Yang Jiao, Xiaofei Qi
Summary: Acute graft-versus-host disease (aGvHD) is a result of cytokine storm, and targeted therapeutic interventions on cytokines through ubiquitination regulatory pathways may provide a potential approach for aGvHD treatment. This study identified the association of ubiquitin-specific peptidase 11 (USP11) with aGvHD and demonstrated that USP11 played a critical role in the onset and progression of aGvHD. IL-6 was identified as a major effecter in aGvHD induced by USP11, and USP11 inhibited IL-6 degradation by affecting IL-6 ubiquitination.
PHARMACOLOGICAL RESEARCH
(2023)
Review
Immunology
Eileen Haring, Robert Zeiser, Petya Apostolova
Summary: Both graft-versus-host disease (GVHD) and inflammatory bowel disease (IBD) are immunologically mediated diseases of the intestine, sharing several key features in their onset and development including intestinal tissue damage and involvement of cytokines.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Mia Shepherdson, Shalem Leemaqz, Gurmeet Singh, Courtney Ryder, Shahid Ullah, Karla Canuto, Joanne P. Young, Timothy J. Price, Ross A. McKinnon, Stephen J. Pandol, Claire T. Roberts, Savio George Barreto
Summary: This study found a significant decrease in incidence of gastrointestinal adenocarcinomas in individuals aged >50 years over the last 30 years, while younger individuals showed no significant change and even a trend towards an increase. The incidence was lower in Indigenous patients compared to non-Indigenous patients, but Indigenous patients had worse survival rates.
Review
Biophysics
Ashleigh P. P. Scott, Andrea Henden, Glen A. A. Kennedy, Siok-Keen Tey
Summary: Acute gastrointestinal graft versus host disease (GI-GVHD) is a serious complication of allogeneic haematopoietic cell transplantation (HCT) with limited diagnostic methods. Innovative investigations using tissue-based biomarker assessment and molecular imaging by positron emission tomography (PET) have the potential to accurately guide GI-GVHD management. This article reviews the evidence regarding GI-GVHD diagnosis and explores the evolving role of PET in predicting or diagnosing GI-GVHD.
BONE MARROW TRANSPLANTATION
(2023)
Article
Hematology
Masaaki Hotta, Atsushi Satake, Hideaki Yoshimura, Shinya Fujita, Yuta Katayama, Shuichi Ota, Hitoshi Hanamoto, Tatsuo Oyake, Shigeki Ito, Masaya Okada, Takahisa Nakanishi, Tomoki Ito, Kazuyoshi Ishii, Shosaku Nomura
Summary: Early prediction of nonrelapse mortality (NRM) in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) is challenging. Using plasma biomarkers ST2 and Reg3 alpha, along with the MAGIC algorithm, can help identify individuals at high risk for NRM. By analyzing blood samples and calculating risk scores, patients can be categorized into low-risk and high-risk groups for predicting the cumulative incidence of 6-month NRM.
TRANSPLANTATION AND CELLULAR THERAPY
(2021)
Article
Medicine, Research & Experimental
Brent R. Logan, Denggang Fu, Alan Howard, Mingwei Fei, Jianqun Kou, Morgan R. Little, Djamilatou Adom, Fathima A. Mohamed, Bruce R. Blazar, Philip R. Gafken, Sophie Paczesny
Summary: This study identifies 5 biomarkers associated with the risk of developing cGVHD in PB and BM recipients. These biomarkers can be used to predict the occurrence of cGVHD with high accuracy.
JOURNAL OF CLINICAL INVESTIGATION
(2023)
Article
Surgery
Justine Khodr, Philippe Zerbib, Moshe Rogosnitzky, Leonardo Magro, Stephanie Truant, Ibrahim Yakoub-Agha, Alain Duhamel, David Seguy
Summary: For patients with severe GI-aGVHD, consideration should be given to DE surgery when resistance to corticosteroids is identified. Data shows a significant improvement in survival rate after DE operation, with a trend towards reducing sepsis-related mortality.
Article
Hematology
Sarah M. Bowers, Bernard Ng, Sayeh Abdossamadi, Amina Kariminia, David A. Cabral, Geoffrey D. E. Cuvelier, Kirk R. Schultz, Kelly L. Brown
Summary: Adenosinergic signaling has context-specific effects on immune cells, particularly on lymphocytes. Changes in ADA2 enzyme activity may be associated with the onset of chronic GVHD.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Pathology
Alexander S. Taylor, Natalia Liu, Jiayun M. Fang, Nicole Panarelli, Lili Zhao, Jerome Cheng, Purva Gopal, Suntrea Hammer, Jing Sun, Henry Appelman, Maria Westerhoff
Summary: Cribriform comedo-type adenocarcinoma, previously recognized as a subtype in colon cancer, was found in 18.6% of cases in the study. It was associated with certain poor prognostic features like positive lymph nodes and increased depth of invasion, but did not show significantly worse survival outcomes compared to other colon cancer cases. The study suggests that while identifying CC may have some clinical relevance, it may not necessarily warrant its own subtype classification due to the presence of similar morphological features in other colon cancer cases.
JOURNAL OF CLINICAL PATHOLOGY
(2022)
Article
Anatomy & Morphology
Zhikai Chi, Jyoti Balani, Purva Gopal, Lan Peng, Suntrea Hammer
Summary: This study compared the immunohistochemistry of esophageal squamous cell carcinoma (SCC) and adenocarcinoma (adenoCA), finding that p40 and p63 were sensitive and specific for the diagnosis of esophageal SCC. However, the immunoreactivity of p40 and p63 was significantly lower in well-differentiated SCC compared to higher-grade tumors. Therefore, caution should be taken when interpreting immunohistochemistry results for small biopsy specimens, especially in well-differentiated components.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
(2021)
Article
Anatomy & Morphology
Nirali Desai, Said Albahra, Elena Lucas, Amit G. Singal, Suntrea T. G. Hammer, Purva Gopal
Summary: The study aimed to investigate the patterns of immunohistochemical stain use in viral esophagitis and the clinicopathologic features of VE. The results showed that some cases required immunohistochemical staining for diagnosis, patients were more likely to have endoscopic ulcer and be immunocompromised, and pretest clinical concern for VE was common.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
(2021)
Article
Biophysics
Jeffrey R. Andolina, Yi-Cheng Wang, Lingyun Ji, David R. Freyer, John E. Levine, Michael A. Pulsipher, Alan S. Gamis, Richard Aplenc, Michael E. Roth, Lauren Harrison, Mitchell S. Cairo
Summary: Adolescent and young adult patients with acute leukemia have poorer outcomes compared to younger patients, and are more prone to developing acute and chronic GVHD following HLA matched sibling donor stem cell transplant.
BONE MARROW TRANSPLANTATION
(2022)
Article
Dermatology
Elysha Kolitz, Elena Lucas, Gregory A. Hosler, Jiwoong Kim, Suntrea Hammer, Cheryl Lewis, Lin Xu, Andrew T. Day, Melissa Mauskar, Jayanthi S. Lea, Richard C. Wang
Summary: This study retrospectively analyzed 36 patients with invasive vulvar squamous cell carcinoma and found that HPV-positive tumors showed higher expression of circular RNAs associated with other cancer pathogenesis.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Article
Oncology
Maureen M. O'Brien, Lingyun Ji, Nirali N. Shah, Susan R. Rheingold, Deepa Bhojwani, Constance M. Yuan, Xinxin Xu, Joanna S. Yi, Andrew C. Harris, Patrick A. Brown, Michael J. Borowitz, Olga Militano, John Kairalla, Meenakshi Devidas, Elizabeth A. Raetz, Lia Gore, Mignon L. Loh
Summary: The study aims to evaluate the efficacy and safety of inotuzumab ozogamicin in pediatric and adolescent patients with relapsed or refractory B-cell acute lymphoblastic leukemia. The results show that inotuzumab ozogamicin is effective and well tolerated in CD22-positive B-ALL patients. Side effects include sinusoidal obstruction syndrome and cytopenias. Partial CD22 expression and lower CD22 site density are associated with decreased response to inotuzumab ozogamicin.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Hematology
Geoffrey D. E. Cuvelier, Bernard Ng, Sayeh Abdossamadi, Eneida R. Nemecek, Alexis Melton, Carrie L. Kitko, Victor A. Lewis, Tal Schechter, David A. Jacobsohn, Andrew C. Harris, Michael A. Pulsipher, Henrique Bittencourt, Sung Won Choi, Emi H. Caywood, Kimberly A. Kasow, Monica Bhatia, Benjamin R. Oshrine, Sonali Chaudhury, Donald Coulter, Joseph H. Chewning, Michael Joyce, Sureyya Savasan, Anna B. Pawlowska, Gail C. Megason, David Mitchell, Alexandra C. Cheerva, Anita Lawitschka, Elena Ostroumov, Kirk R. Schultz
Summary: This study aimed to identify pediatric cGVHD biomarkers that supplement current clinical criteria and differentiate between cGVHD and non-cGVHD. The findings suggest that decreases in regulatory natural killer cells, naive CD4 T helper cells, and naive regulatory T cells, as well as elevated levels of CXCL9, CXCL10, CXCL11, ST2, ICAM-1, and soluble CD13 (sCD13) may characterize the onset of cGVHD. A machine learning-based classifier was developed, combining these biomarkers with clinical factors to improve the diagnosis of cGVHD in children.
Letter
Biophysics
Gabrielle Meyers, Mehdi Hamadani, Michael Martens, Haris Ali, Patrice Chevallier, Hannah Choe, Andrew C. Harris, Ernst Holler, Eric van Hooren, Willem Klaassen, Eric Leifer, Ypke van Oosterhout, Lia Perez, Iskra Pusic, Matthias Stelljes, Walter van der Velden, Emanuele Ammatuna, David Beauvais, Jerome Cornillon, Richard T. Maziarz, Johannes Schetelig, Jennifer Romeril, Margaret L. MacMillan, John E. Levine, Gerard Socie
BONE MARROW TRANSPLANTATION
(2023)
Article
Oncology
Carrie L. Kitko, Catherine M. Bollard, Mitchell S. Cairo, Joseph Chewning, Terry J. Fry, Michael A. Pulsipher, Shalini Shenoy, Donna A. Wall, John E. Levine
Summary: Since 2013, the Children's Oncology Group cellular therapy-based trials have advanced the field and set new standards of care for pediatric cancer. Key findings include improved survival with tandem autologous transplant for neuroblastoma and atypical teratoid/rhabdoid brain tumors, safer single umbilical cord blood donor compared to two donors, lack of survival improvement with killer immunoglobulin receptor (KIR) mismatched donors for pediatric acute myeloid leukemia, and the importance of minimal residual disease assessment for predicting relapse in acute lymphoblastic leukemia. Future plans include optimizing donor selection, using engineered cellular therapies, and developing better treatments for therapy toxicities.
PEDIATRIC BLOOD & CANCER
(2023)
Editorial Material
Hematology
John E. Levine
Article
Hematology
Andrew D. Trunk, Katherine Radwanski, Cheryl Heber, Ashley Taylor, FenFen Hsieh, Andrew Harris, Catherine J. Lee, John D. Phillips, Daniel R. Couriel
Summary: Extracorporeal photopheresis (ECP) is commonly used to treat steroid-refractory acute and chronic graft-versus-host disease (GVHD). Cryopreservation of ECP-treated cells is being investigated as a strategy to increase access to this therapy.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Hematology
Santosh Putta, Bradford A. Young, John E. Levine, Ran Reshef, Ryotaro Nakamura, Christopher Strouse, Miguel -Angel Perales, Alan Howard, Polly Pine, Ju Shi, Peixin Zhang, Vincent T. Ho, Wael Saber
Summary: This study aimed to determine blood biomarkers that could identify high-risk patients for hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) shortly after hematopoietic cell transplantation (HCT). The study found that a combination of up to 5 protein biomarkers may provide a prognostic tool for identifying patients at risk for VOD/SOS.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Hematology
Hannah-Lise T. Schofield, Vanessa A. Fabrizio, Suzanne Braniecki, Wendy Pelletier, Hesham Eissa, Beverly Murphy, Joseph Chewning, Karen D. Barton, Leanne M. Embry, John E. Levine, Kirk R. Schultz, Kristin M. Page
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Article
Anatomy & Morphology
Zhikai Chi, Jyoti Balani, Purva Gopal, Lan Peng, Suntrea Hammer
Summary: This study analyzed the immunohistochemical characteristics of p40 and p63 in esophageal squamous cell carcinoma (SCC) across different grades of differentiation, finding significant differences in immunoreactivity for p40 and p63. Additionally, the sensitivity of esophageal SCC components was higher compared to esophageal adenocarcinoma components.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
(2021)
Article
Anatomy & Morphology
Nirali Desai, Said Albahra, Elena Lucas, Amit G. Singal, Suntrea T. G. Hammer, Purva Gopal
Summary: IHC is frequently used in VE biopsies even when viral inclusions are present, and in patients without concerning histology or clinical symptoms for VE. History, endoscopic findings, and histology play a role in guiding the use of IHC in VE.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
(2021)